Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tezosentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 0.79 |
| ▸ | EDNRB known ✓ | P24530 | 19/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tezosentan SCHEMBL387772 | 1.00 | EDNRA (0.79) | EDNRAEDNRB | |
| Tezosentan SCHEMBL4524 | 0.99 | EDNRA (0.80) | EDNRAEDNRB | |
| Tezosentan SCHEMBL29409604 | 0.99 | EDNRA (0.80) | EDNRAEDNRB | |
| Tezosentan SCHEMBL6963555 | 0.99 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL6974621 | 0.92 | EDNRA (0.78) | EDNRAEDNRB | |
| Clazosentan SCHEMBL26662037 | 0.92 | EDNRA (0.78) | EDNRAEDNRB | |
| SCHEMBL7503358 | 0.92 | EDNRA (0.69) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29379450 | 0.91 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL1983603 | 0.91 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29581324 | 0.91 | EDNRA (0.79) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190167679-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-06-06 | — | — | US | claimed |
| US-20260116886-A1 | DEUTERATED sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-4605394-A1 | PYRIMIDINE SGC STIMULATORS | Tisento Therapeutics Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4605080-A1 | TREATMENT OF MITOCHONDRIAL DISEASES WITH SGC STIMULATORS | Tisento Therapeutics Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20240366596-A1 | TREATMENT OF HFPEF IN POST-MENOPAUSAL WOMEN WITH AN SGC STIMULATOR | CYCLERION THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240208979-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240207265-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| EP-4376843-A1 | TREATMENT OF HFPEF IN POST-MENOPAUSAL WOMEN WITH AN SGC STIMULATOR | Cyclerion Therapeutics, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-2741778-A1 | POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS | Ascendis Pharma A/S (DK) | 2014-06-18 | — | — | EP | disclosed |
| EP-2741779-A1 | HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS | Ascendis Pharma A/S (DK) | 2014-06-18 | — | — | EP | disclosed |
| CN-102573913-B | Biodegradable polyethylene glycol-based water-insoluble hydrogels | ASCENDIS PHARMA AS | 2014-06-18 | — | — | CN | disclosed |
| WO-2013160340-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA A/S (DK) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013024048-A1 | POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024047-A1 | HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-2459220-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| EP-1060749-A1 | Aqueous pharmaceutical composition comprising Tezosentan | Actelion Pharmaceuticals Ltd. (CH) | 2000-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | EDNRA 2118/4885EDNRB 1631/4885 |
| US-20240366596-A1 | TREATMENT OF HFPEF IN POST-MENOPAUSAL WOMEN WITH AN SGC STIMULATOR | GUCY1A2, GUCY1A1, GUCY1B2 | EDNRA 43/4885EDNRB 37/4885 |
| US-20240208979-A1 | sGC STIMULATORS | GMPS, PRKG1, CGAS | EDNRA 129/4885EDNRB 149/4885 |
| US-20260116886-A1 | DEUTERATED sGC STIMULATORS | PDE2A, PRKG1, GUCY1A2 | EDNRA 181/4885EDNRB 292/4885 |
| US-20190167679-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | EDNRA 121/4885EDNRB 138/4885 |
| US-20240207265-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1A1, GUCY1B2 | EDNRA 200/4885EDNRB 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.